Chronic Phase CML Model for Predicting Complete Cytogenetic Response to Imatinib Mesylate

Purpose: To determine the chances of having a complete cytogenetic response following imatinib mesylate therapy in a Philadelphia chrosome positive CML in chronic phase.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with Philadelphia chromosome positive CML in chronic phase?

Yes

Percent of cells positive for the Philadelphia chromosome before therapy (enter from 0 to 100)

Platelet count prior to therapy

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Risk score

Risk group for complete cytogenetic response

Percentage of patients achieving a complete cytogenetic response

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Risk Score for First Chronic Phase of CML (CML-CP Score)
Severity, Prognosis, Stage

Therapy

Options
- Risk Score for First Chronic Phase of CML (CML-CP Score)
Selection
- Risk Score for First Chronic Phase of CML (CML-CP Score)

Monitoring

Response To Therapy
- Risk Score for First Chronic Phase of CML (CML-CP Score)
- European Treatment and Outcome Study for CML (EUTOS) Score

Specialty

Hematology Oncology

Objective

risk factors

ICD-10

C92.1 - Chronic myeloid leukaemia [CML], BCR/ABL-positive

Info

Purpose: To determine the chances of having a complete cytogenetic response following imatinib mesylate therapy in a Philadelphia chrosome positive CML in chronic phase.

Specialty: Hematology Oncology

Objective: risk factors

ICD-10: C92.1,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path